Osage University Partners (OUP), a Philadelphia area-based venture capital firm, closed its second fund at $215m.
Consistent with the strategy employed by its first fund, Osage University Partners II, L.P., invests exclusively in startups that are commercializing university research across a wide range of life science and technology sectors and all stages of development, from seed to late stage/pre-IPO.
Led by Managing Partners Marc Singer, William Harrington, MD, and Robert Adelson, OUP II will invest in spinouts from its partner universities and research institutions, which typically hold co-investment rights in their spinouts and assign to the fund in return for a share of its profit.
The fund has signed exclusive contracts with 16 University Partners and also has non-exclusive Associate Partner relationships with an additional 54 universities and research institutions.
Osage University Partners’ initial fund has recently exited Receptos (RCPT), Aerie (AERI), Otonomy (OTIC), Immune Design (IMDZ), and AGTC (AGTC).